The European Medicines Agency said its safety committee concluded that a warning about unusual blood clots with low blood platelets should be added to the product information for Johnson & Johnson’s coronavirus vaccine, which it said had benefits that outweighed the risk of “very rare” side effects. All eight of the U.S. cases, after more than 7 million vaccinations, occurred in people under 60 years of age within three weeks after vaccination, and mostly in women. The cases reviewed were very similar to the cases that occurred with the COVID-19 vaccine developed by AstraZeneca , the EMA said. The rollout of Johnson & Johnson’s vaccine in Europe was paused by the company.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.